Bogdan Mitran
Researcher at Institutionen för läkemedelskemi; Translationell avbildning med PET
- E-mail:
- bogdan.mitran@ilk.uu.se
- Visiting address:
- Dag Hammarskjöldsv 14C, 3tr
- Postal address:
- Dag Hammarskjöldsv 14C, 3tr
751 83 Uppsala
- ORCID:
- 0000-0001-7921-3268
More information is available to staff who log in.
Short presentation
Biomedical engineer pursuing my Ph.D. in the field of nuclear medicine. I have a strong research background with expertise in the development and preclinical evaluation of radiolabeled compounds.
My research and career interests lie in molecular imaging, specializing in the use of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for imaging of various biomarkers in oncology.
Publications
Selection of publications
- Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate (2018)
- Radiocobalt-labeled anti-HER1 affibody molecule DOTA-Z(EGFR:2377) for imaging of low HER1 expression in prostate cancer pre-clinical model (2017)
- High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26 (2017)
- Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. (2016)
- Evaluation of 99mTc-ZIGF1R:4551-GGGC Affibody Molecule, a New Construct for Imaging the Insulin-like Growth Factor Type 1 Receptor Expression (2014)
Recent publications
- Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β (2023)
- Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer (2020)
- Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model (2020)
- Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer (2020)
- Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules (2020)
All publications
Articles
- Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β (2023)
- Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer (2020)
- Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model (2020)
- Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer (2020)
- Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules (2020)
- Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer (2019)
- Molecular Design of HER3-Targeting Affibody Molecules (2019)
- Comparative Evaluation of Two DARPin Variants (2019)
- Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts (2019)
- Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours (2019)
- Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-Z(EGFR:2377) (2019)
- Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26 (2019)
- Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26 (2019)
- Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer (2019)
- Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart (2019)
- Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules (2019)
- Optimization of HER3 expression imaging using affibody molecules (2019)
- Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake (2019)
- Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 (2019)
- Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 (2019)
- Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting (2019)
- Affibody-derived drug conjugates (2018)
- Selection of the most optimal ADAPT6-based probe for imaging of HER2 using PET and SPECT (2018)
- Radionuclide tumor targeting using ADAPT scaffold proteins (2018)
- Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga (2018)
- Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate (2018)
- GRPR-targeted radiotherapy using the Lu-177-labeled GRPR-antagonist DOTAGA-PEG(2)-RM26 (2018)
- Selection of optimal macrocyclic chelator for high contrast PET imaging of gastrin releasing peptide receptor using cobalt-labeled bombesin antagonist RM26 (2018)
- Imaging contrast of HER3 expression using monomeric affibody-based imaging probe can be improved by co-injection of affibody trimer (2018)
- Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules (2018)
- Comparative evaluation of anti-EFGR affibody molecules labelled with gallium-68 and zirconium-89 using desferrioxamine B as a chelator (2018)
- Preclinical Evaluation of [Ga-68]Ga-DFO-ZEGFR:2377 (2018)
- Optimization of molecular design of Ga-68-labeled affibody molecule for PET imaging of HER3 expression (2018)
- PP15 89Zr-Siderophore-Affibody conjugates for imaging EGFR expression (2018)
- Cyclic versus Noncyclic Chelating Scaffold for Zr-89-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression (2018)
- Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Molecular Imaging of HER2 Expression in Cancer Using SPECT (2018)
- Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors (2018)
- Development of a PET Imaging Approach for Selection of Patients for Affibody-Based PNA-Mediated Pretargeted Radionuclide Therapy (2018)
- Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy (2018)
- Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting (2018)
- Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting (2017)
- In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin- binding therapeutic affibody construct (2017)
- The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule (2017)
- Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m (2017)
- Radiocobalt-labeled anti-HER1 affibody molecule DOTA-Z(EGFR:2377) for imaging of low HER1 expression in prostate cancer pre-clinical model (2017)
- Novel high affinity affibody for radionuclide imaging of VEGFR2 in glioma vasculature (2017)
- High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26 (2017)
- GRPR-Targeted Radiotherapy (2017)
- Influence of composition of cysteine-containing peptide based chelators on biodistribution of Tc-99m-labelled anti-EGFR affibody molecules (2017)
- Optimization of affibody molecule for imaging of HER3 expression (2017)
- Evaluation of radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression (2017)
- Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting (2016)
- Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR (2016)
- PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR (2016)
- Evaluation of Affibody Molecules for Radionuclide Imaging of Carbonic Abhydrase IX Expression In Vivo (2016)
- Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX (2016)
- Influence of the N-terminal amino acid sequence on imaging properties of In-111-labeled anti-HER2 scaffold protein ADAPT6 (2016)
- Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6 (2016)
- Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct Z(VEGFR2)-Bp(2) (2016)
- Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. (2016)
- In vivo evaluation of pharmacokinetics, tumors targeting and therapeutic efficacy of a novel format of HER3-targeting affibody molecule with prolonged blood circulation (2016)
- Imaging of EGFR Expression Using 99mTC-Labelled ZEGFR:2377 Affibody Molecule (2016)
- Development and Evaluation of Radiocobalt-labelled Affibody Molecule for Next Day PET Imaging of HER3 Expression (2016)
- Synthesis of 11C-labelled Sulfonyl Carbamates via a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols and [11C]CO (2016)
- Synthesis of C-11-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [C-11]CO (2016)
- Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules (2016)
- Affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting (2015)
- Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression (2015)
- Development of radiocobalt-labeled GRPR antagonist NOTA-PEG2-RM26. (2015)
- Influence of chelators on targeting properties of In-111 and Ga-68 labeled GRPR antagonist (2015)
- Affibody-mediated PET imaging of HER3 expression in malignant tumours (2015)
- The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 (2015)
- Evaluation of 99mTc-ZIGF1R:4551-GGGC Affibody Molecule, a New Construct for Imaging the Insulin-like Growth Factor Type 1 Receptor Expression (2014)
- Influence of chelators on biodistribution and targeting properties of GRPR antagonist (2014)
- PET Imaging of HER3-Expression in Tumours Using a 68Ga-Labeled Affibody Molecule (2014)
- The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a Ga-68-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin (2014)
- Positron Emission Tomography imaging of CD69 in a murine model of rheumatoid arthritis
Books
